Why the study?
Recent contrasting evidence exists regarding dual RAAS blockade, and very few studies have evaluated its effectiveness in diabetic nephropathy patients with albuminuria or proteinuria.
Key points are not available for this paper at this time.
Population
Diabetic nephropathy patients with albuminuria and proteinuria
Comparison
Dual RAAS blockade dose-response analysis
Design
Meta-analysis
Dual RAAS blockade may reduce albuminuria dose-dependently in DN; leaves open hard-outcome and safety data from larger trials.
Objective: Treatment with renin angiotensin aldosterone system (RAAS) blockade including angiotensin-converting enzyme inhibitors (ACEis) and angiotensin II receptor blockers (ARBs) have been shown to improve clinical outcomes. However, recent contrasting evidence regarding the dual RAAS blockade has also been presented. Very few studies have investigated the effectiveness of this dual blockade among diabetic nephropathy (DN) patients in association with albuminuria or proteinuria.
No takes yet. Share an insight, caveat, or question.
Dalbhi et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: